What is HC Wainwright’s Estimate for Alphatec Q2 Earnings?

Alphatec Holdings, Inc. (NASDAQ:ATEC) – Equities research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Alphatec in a report released on Wednesday, February 25th. HC Wainwright analyst S. Lee expects that the medical technology company will post earnings of $0.01 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Alphatec’s FY2026 earnings at $0.09 EPS and FY2030 earnings at $1.13 EPS.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $212.93 million for the quarter, compared to analysts’ expectations of $212.67 million. During the same quarter last year, the business posted ($0.23) EPS. The business’s quarterly revenue was up 20.4% on a year-over-year basis.

ATEC has been the topic of several other reports. Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Barclays boosted their price objective on Alphatec from $23.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, January 7th. TD Cowen reiterated a “buy” rating on shares of Alphatec in a research report on Tuesday, January 27th. Piper Sandler reiterated an “overweight” rating on shares of Alphatec in a research note on Wednesday, February 25th. Finally, Morgan Stanley set a $23.00 price target on shares of Alphatec in a research note on Tuesday, December 2nd. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.82.

Alphatec Trading Down 1.1%

NASDAQ:ATEC opened at $13.47 on Monday. Alphatec has a 12 month low of $8.81 and a 12 month high of $23.29. The company has a current ratio of 2.06, a quick ratio of 1.28 and a debt-to-equity ratio of 40.35. The firm’s 50 day moving average is $16.59 and its 200 day moving average is $17.10. The stock has a market capitalization of $2.04 billion, a PE ratio of -14.18 and a beta of 1.02.

Insider Activity

In related news, EVP David Sponsel sold 60,425 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $13.79, for a total value of $833,260.75. Following the sale, the executive vice president owned 349,500 shares in the company, valued at approximately $4,819,605. This trade represents a 14.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick Miles sold 100,000 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $21.01, for a total value of $2,101,000.00. Following the completion of the transaction, the chief executive officer owned 5,135,398 shares in the company, valued at $107,894,711.98. This represents a 1.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 1,336,125 shares of company stock worth $27,174,878. Company insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Voloridge Investment Management LLC purchased a new stake in shares of Alphatec in the 4th quarter valued at $321,000. Susquehanna Portfolio Strategies LLC bought a new stake in Alphatec in the fourth quarter worth $681,000. Numerai GP LLC purchased a new stake in Alphatec during the fourth quarter valued at about $757,000. Occudo Quantitative Strategies LP grew its stake in shares of Alphatec by 235.4% during the fourth quarter. Occudo Quantitative Strategies LP now owns 269,798 shares of the medical technology company’s stock valued at $5,677,000 after buying an additional 189,348 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Alphatec by 292.2% in the fourth quarter. Millennium Management LLC now owns 2,225,927 shares of the medical technology company’s stock worth $46,834,000 after buying an additional 1,658,349 shares during the period. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.